300485 赛升药业
未开盘 11-27 09:30:00
资讯
新帖
简况
赛升药业(300485)11月20日股东户数2.75万户，较上期减少1.65%
证券之星 · 11-26 17:04
赛升药业(300485)11月20日股东户数2.75万户，较上期减少1.65%
赛升药业最新公告：子公司药品生产许可证变更获批
证券之星 · 11-20
赛升药业最新公告：子公司药品生产许可证变更获批
赛升药业(300485)10月10日股东户数2.83万户，较上期减少1.87%
证券之星 · 10-25
赛升药业(300485)10月10日股东户数2.83万户，较上期减少1.87%
赛升药业(300485.SZ)发布前三季度业绩，净亏损9819.82万元
智通财经 · 10-24
赛升药业(300485.SZ)发布前三季度业绩，净亏损9819.82万元
赛升药业最新公告：拟择机出售绿竹生物及康乐卫士股票
证券之星 · 10-24
赛升药业最新公告：拟择机出售绿竹生物及康乐卫士股票
赛升药业(300485.SZ)：公司相关产品获批用于急性缺血性脑卒中患者
智通财经 · 10-23
赛升药业(300485.SZ)：公司相关产品获批用于急性缺血性脑卒中患者
赛升药业(300485)10月10日股东户数2.83万户，较上期减少1.87%
证券之星 · 10-16
赛升药业(300485)10月10日股东户数2.83万户，较上期减少1.87%
赛升药业：截至2024年9月30日，公司股东户数为28837
证券之星 · 10-10
赛升药业：截至2024年9月30日，公司股东户数为28837
赛升药业(300485)9月30日股东户数2.88万户，较上期减少0.18%
证券之星 · 10-10
赛升药业(300485)9月30日股东户数2.88万户，较上期减少0.18%
赛升药业：公司在研项目属于1类新药的有安替安吉肽、血管生成抑肽、GGE-3等
证券之星 · 08-30
赛升药业：公司在研项目属于1类新药的有安替安吉肽、血管生成抑肽、GGE-3等
赛升药业最新公告：2024年上半年净利润亏损1.05亿元
证券之星 · 08-27
赛升药业最新公告：2024年上半年净利润亏损1.05亿元
赛升药业(300485.SZ)发布上半年业绩，由盈转亏至1.05亿元
智通财经 · 08-27
赛升药业(300485.SZ)发布上半年业绩，由盈转亏至1.05亿元
赛升药业（300485）8月27日主力资金净买入133.91万元
证券之星 · 08-27
赛升药业（300485）8月27日主力资金净买入133.91万元
赛升药业（300485）8月23日主力资金净卖出84.08万元
证券之星 · 08-23
赛升药业（300485）8月23日主力资金净卖出84.08万元
赛升药业：截至2024年8月9日，公司股东户数为29166
证券之星 · 08-13
赛升药业：截至2024年8月9日，公司股东户数为29166
赛升药业（300485）8月6日主力资金净买入535.71万元
证券之星 · 08-06
赛升药业（300485）8月6日主力资金净买入535.71万元
医药股午后异动频频，多瑞医药20cm涨停，舒泰神、睿智医药、赛升药业、广生堂均涨超10%，佛慈制药封板，亨迪药业涨逾9%。
智通财经 · 08-06
医药股午后异动频频，多瑞医药20cm涨停，舒泰神、睿智医药、赛升药业、广生堂均涨超10%，佛慈制药封板，亨迪药业涨逾9%。
【华证ESG】赛升药业（300485）获得B评级，行业排名第175
证券之星 · 08-06
【华证ESG】赛升药业（300485）获得B评级，行业排名第175
赛升药业(300485.SZ)：人源化抗VEGF单抗注射液临床试验获伦理委员会审批报告
智通财经 · 07-22
赛升药业(300485.SZ)：人源化抗VEGF单抗注射液临床试验获伦理委员会审批报告
【赛升药业(300485.SZ)：人源化抗VEGF单抗注射液临床试验获伦理委员会审批报告】智通财经APP讯，赛升药业(300485.
智通财经 · 07-22
【赛升药业(300485.SZ)：人源化抗VEGF单抗注射液临床试验获伦理委员会审批报告】智通财经APP讯，赛升药业(300485.
加载更多
公司概况
公司名称：
北京赛升药业股份有限公司
所属行业：
医药制造业
上市日期：
2015-06-26
主营业务：
北京赛升药业股份有限公司的主营业务为注射针剂的研发、生产及销售,主导产品为生物生化药品，涉及心脑血管类疾病、免疫性疾病(抗肿瘤)和神经系统疾病三大用药领域。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。公司及赛而生物发明专利“单唾液酸四己糖神经节苷脂的制备方法以及单唾液酸四己糖神经节苷脂钠注射液或冻干粉针”(专利号ZL200910085592.0)荣获第二十届中国专利优秀奖。纤溶酶注射液被评为2023年年度生化生物企业优秀品牌。
发行价格：
38.46
{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"赛升药业","latestPrice":7.85,"timestamp":1732669347000,"preClose":7.85,"halted":0,"volume":0,"delay":0,"floatShares":274000000,"shares":482000000,"eps":-0.3983,"marketStatus":"未开盘","marketStatusCode":0,"change":0,"latestTime":"11-27 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.3983,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732671000000},"adr":0,"adjPreClose":7.85,"symbolType":"stock","openAndCloseTimeList":[[1732671000000,1732678200000],[1732683600000,1732690800000]],"highLimit":8.64,"lowLimit":7.06,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"pbRate":1.14,"roa":"--","roe":"--","epsLYR":0.21,"marketValue":3781000000,"floatMarketCap":2149000000,"peRate":-19.708763,"changeRate":0,"turnoverRate":0,"status":2},"requestUrl":"/m/hq/s/300485","defaultTab":"news","newsList":[{"id":"2486026374","title":"赛升药业(300485)11月20日股东户数2.75万户，较上期减少1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486026374","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486026374?lang=zh_cn&edition=full","pubTime":"2024-11-26 17:04","pubTimestamp":1732611872,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2024年11月20日公司股东户数为2.75万户，较10月18日减少463.0户，减幅为1.65%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至11月20日，生物制品行业平均股东户数为3.39万户。从股价来看，2024年10月18日至2024年11月20日，赛升药业区间涨幅为3.62%，在此期间股东户数减少463.0户，减幅为1.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112600028665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0028","300485","BK0046"],"gpt_icon":0},{"id":"2484316969","title":"赛升药业最新公告：子公司药品生产许可证变更获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2484316969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484316969?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:40","pubTimestamp":1732092034,"startTime":"0","endTime":"0","summary":"赛升药业公告，子公司赛而生物近日获得北京市药品监督管理局颁发的《药品生产许可证》，变更事项为：同意在《药品生产许可证》天津市蓟州区京津州河科技产业园腾飞街2号地址项下“原料药综合车间：合成生产线”新增生产范围：“原料药（达格列净）（仅限注册申报使用）”。本次新增生产范围待取得药品批准证明文件并通过药品GMP符合性检查后方可正式生产使用。本次变更涉及生产范围的新增，有利于丰富赛而生物的产品结构，更好地满足市场需求。以上变更短期内对公司业绩无重大影响，对未来长期影响暂无法预估。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000027831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","BK0012","300485"],"gpt_icon":0},{"id":"2478060349","title":"赛升药业(300485)10月10日股东户数2.83万户，较上期减少1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478060349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478060349?lang=zh_cn&edition=full","pubTime":"2024-10-25 17:11","pubTimestamp":1729847496,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2024年10月10日公司股东户数为2.83万户，较9月30日减少539.0户，减幅为1.87%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至10月10日，生物制品行业平均股东户数为3.35万户。从股价来看，2024年9月30日至2024年10月10日，赛升药业区间跌幅为0.75%，在此期间股东户数减少539.0户，减幅为1.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500030214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","300485","BK0028","BK0239","BK0046"],"gpt_icon":0},{"id":"2477381106","title":"赛升药业(300485.SZ)发布前三季度业绩，净亏损9819.82万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477381106","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477381106?lang=zh_cn&edition=full","pubTime":"2024-10-24 20:39","pubTimestamp":1729773559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布2024年三季度报告，该公司前三季度营业收入为3.23亿元，同比减少18.01%。归属于上市公司股东的净亏损为9819.82万元。归属于上市公司股东的扣除非经常性损益的净利润为1754.75万元，同比减少21.27%。基本每股亏损为0.2元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0046","BK0239","BK0012","300485"],"gpt_icon":0},{"id":"2477150710","title":"赛升药业最新公告：拟择机出售绿竹生物及康乐卫士股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2477150710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477150710?lang=zh_cn&edition=full","pubTime":"2024-10-24 18:20","pubTimestamp":1729765249,"startTime":"0","endTime":"0","summary":"赛升药业公告称，公司拟根据证券市场情况择机出售所持有的绿竹生物及康乐卫士股票。公司目前持有绿竹生物股票1375.15万股，占其总股本的6.79%；持有康乐卫士股票136.4万股；占其总股本的0.49%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400031173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0046","300485","BK0012"],"gpt_icon":0},{"id":"2477632332","title":"赛升药业(300485.SZ)：公司相关产品获批用于急性缺血性脑卒中患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2477632332","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477632332?lang=zh_cn&edition=full","pubTime":"2024-10-23 12:25","pubTimestamp":1729657515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)公告，公司已按国家药品监督管理局《关于单唾液酸四己糖神经节苷脂钠制剂启动确证性临床试验的通知》及有关规定，在三年内按要求完成了符合现行要求的确证性临床试验，向国家局药审中心申报补充申请，获得了药品补充申请批准，对该品说明书进行了修订，修订后适应症用于急性缺血性脑卒中患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0046","300485","BK0012","BK0239"],"gpt_icon":0},{"id":"2475595866","title":"赛升药业(300485)10月10日股东户数2.83万户，较上期减少1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475595866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475595866?lang=zh_cn&edition=full","pubTime":"2024-10-16 17:04","pubTimestamp":1729069442,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2024年10月10日公司股东户数为2.83万户，较9月30日减少539.0户，减幅为1.87%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至10月10日，生物制品行业平均股东户数为3.36万户。从股价来看，2024年9月30日至2024年10月10日，赛升药业区间跌幅为0.75%，在此期间股东户数减少539.0户，减幅为1.87%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101600026500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0012","300485","BK0046"],"gpt_icon":0},{"id":"2474791556","title":"赛升药业：截至2024年9月30日，公司股东户数为28837","url":"https://stock-news.laohu8.com/highlight/detail?id=2474791556","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474791556?lang=zh_cn&edition=full","pubTime":"2024-10-10 17:01","pubTimestamp":1728550917,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)10月10日在投资者关系平台上答复投资者关心的问题。投资者：请问截止2024年9月30日公司股东人数是多少？谢谢赛升药业董秘：您好，截至2024年9月30日，公司股东户数为28837。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101000030175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0046","300485","BK0012"],"gpt_icon":0},{"id":"2474879135","title":"赛升药业(300485)9月30日股东户数2.88万户，较上期减少0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474879135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474879135?lang=zh_cn&edition=full","pubTime":"2024-10-10 17:00","pubTimestamp":1728550859,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2024年9月30日公司股东户数为2.88万户，较9月20日减少53.0户，减幅为0.18%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.35万户。从股价来看，2024年9月20日至2024年9月30日，赛升药业区间涨幅为26.87%，在此期间股东户数减少53.0户，减幅为0.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101000030096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0046","BK0239","BK0028","300485"],"gpt_icon":0},{"id":"2463812197","title":"赛升药业：公司在研项目属于1类新药的有安替安吉肽、血管生成抑肽、GGE-3等","url":"https://stock-news.laohu8.com/highlight/detail?id=2463812197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463812197?lang=zh_cn&edition=full","pubTime":"2024-08-30 18:05","pubTimestamp":1725012326,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)08月30日在投资者关系平台上答复投资者关心的问题。投资者：公司在研制的有没有独家创新药？是治疗什么病症的？能详细介绍一下吗赛升药业董秘：您好，公司在研项目属于1类新药的有安替安吉肽、血管生成抑肽、GGE-3等。其中，安替安吉肽肺癌适应症为胃癌等实体肿瘤治疗，目前处于I期临床阶段；血管生成抑肽适应症为肿瘤治疗，目前处于I期临床阶段；GGE-3适应症为阿尔茨海默症、缺血性脑卒中，目前为临床前研究。其他在研新药项目请关注公司披露的临时公告及定期报告中的相关内容。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000036227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0028","BK0239","BK0012","BK0046"],"gpt_icon":0},{"id":"2462158647","title":"赛升药业最新公告：2024年上半年净利润亏损1.05亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462158647","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462158647?lang=zh_cn&edition=full","pubTime":"2024-08-27 16:37","pubTimestamp":1724747852,"startTime":"0","endTime":"0","summary":"赛升药业发布2024年半年度报告，报告期内，公司实现营业收入2.15亿元，同比下降21.03%；净利润亏损1.05亿元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082700026919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"gpt_icon":0},{"id":"2462137215","title":"赛升药业(300485.SZ)发布上半年业绩，由盈转亏至1.05亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462137215","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462137215?lang=zh_cn&edition=full","pubTime":"2024-08-27 16:22","pubTimestamp":1724746953,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布2024年半年度报告，该公司营业收入为2.15亿元，同比减少21.03%。归属于上市公司股东的净亏损为1.05亿元。归属于上市公司股东的扣除非经常性损益的净利润为1808.84万元，同比减少8.11%。基本每股亏损为0.22元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1171606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","300485","BK0028","BK0239","BK0046"],"gpt_icon":0},{"id":"2462139138","title":"赛升药业（300485）8月27日主力资金净买入133.91万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462139138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462139138?lang=zh_cn&edition=full","pubTime":"2024-08-27 15:22","pubTimestamp":1724743326,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月27日收盘，赛升药业报收于6.45元，上涨1.26%，换手率1.04%，成交量2.85万手，成交额1849.72万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：赛升药业2024年一季报显示，公司主营收入1.1亿元，同比下降17.46%；归母净利润-1.91亿元，同比下降23235.01%；扣非净利润1515.78万元，同比上升383.81%；负债率3.96%，投资收益-8297.34万元，财务费用-25.01万元，毛利率66.07%。赛升药业主营业务：注射针剂的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082700019602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","300485","BK0046"],"gpt_icon":0},{"id":"2461558594","title":"赛升药业（300485）8月23日主力资金净卖出84.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461558594","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461558594?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:27","pubTimestamp":1724398063,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月23日收盘，赛升药业报收于6.24元，下跌3.41%，换手率1.0%，成交量2.73万手，成交额1723.6万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：赛升药业2024年一季报显示，公司主营收入1.1亿元，同比下降17.46%；归母净利润-1.91亿元，同比下降23235.01%；扣非净利润1515.78万元，同比上升383.81%；负债率3.96%，投资收益-8297.34万元，财务费用-25.01万元，毛利率66.07%。赛升药业主营业务：注射针剂的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300021315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","300485","BK0046","BK0239"],"gpt_icon":0},{"id":"2459920845","title":"赛升药业：截至2024年8月9日，公司股东户数为29166","url":"https://stock-news.laohu8.com/highlight/detail?id=2459920845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459920845?lang=zh_cn&edition=full","pubTime":"2024-08-13 18:04","pubTimestamp":1723543449,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)08月13日在投资者关系平台上答复投资者关心的问题。投资者：请问截止8月9日盘后公司登记在册的股东人数是多少？谢谢赛升药业董秘：您好，截至2024年8月9日，公司股东户数为29166。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081300036130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","300485","BK0046","BK0239"],"gpt_icon":0},{"id":"2457982460","title":"赛升药业（300485）8月6日主力资金净买入535.71万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457982460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457982460?lang=zh_cn&edition=full","pubTime":"2024-08-06 15:16","pubTimestamp":1722928606,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月6日收盘，赛升药业报收于6.88元，上涨8.35%，换手率4.62%，成交量12.65万手，成交额8615.04万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：赛升药业2024年一季报显示，公司主营收入1.1亿元，同比下降17.46%；归母净利润-1.91亿元，同比下降23235.01%；扣非净利润1515.78万元，同比上升383.81%；负债率3.96%，投资收益-8297.34万元，财务费用-25.01万元，毛利率66.07%。赛升药业主营业务：注射针剂的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080600024823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0239","BK0028","BK0012","BK0046"],"gpt_icon":0},{"id":"2457650060","title":"医药股午后异动频频，多瑞医药20cm涨停，舒泰神、睿智医药、赛升药业、广生堂均涨超10%，佛慈制药封板，亨迪药业涨逾9%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457650060","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457650060?lang=zh_cn&edition=full","pubTime":"2024-08-06 13:29","pubTimestamp":1722922179,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["300149","BK0028","BK0216","BK0239","BK1161","BK1515","BK1574","BK0012","BK0046","159938","301075","300204","002644","300436","300485","09939","301211","BK0077"],"gpt_icon":0},{"id":"2457806055","title":"【华证ESG】赛升药业（300485）获得B评级，行业排名第175","url":"https://stock-news.laohu8.com/highlight/detail?id=2457806055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457806055?lang=zh_cn&edition=full","pubTime":"2024-08-06 10:15","pubTimestamp":1722910555,"startTime":"0","endTime":"0","summary":"日前，华证指数公布了新一期的ESG评级结果，赛升药业获得B评级，在263家制药行业上市公司中排名第175。上海华证指数信息服务有限公司，是一家专业从事指数与指数化投资综合服务的公司，拥有上海证券交易所、深圳证券交易所和香港交易所的指数编制行情授权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080600016753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","159717"],"gpt_icon":0},{"id":"2453756713","title":"赛升药业(300485.SZ)：人源化抗VEGF单抗注射液临床试验获伦理委员会审批报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2453756713","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453756713?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:53","pubTimestamp":1721638403,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)公告，公司研制的“人源化抗VEGF单抗注射液”获得国家癌症中心/中国医学科学院北京协和医学院肿瘤医院伦理委员会审批报告。该药品适应症为转移性结直肠癌等，本次获同意的项目名称为：比较人源化抗VEGF单抗或贝伐珠单抗分别联合奥沙利铂和氟尿嘧啶类一线治疗转移性结直肠癌的有效性、安全性及免疫原性的随机、双盲、平行对照的III期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0046","BK1141","BK1576","BK1583","300485","03347","BK0239","BK0028"],"gpt_icon":0},{"id":"2453567617","title":"【赛升药业(300485.SZ)：人源化抗VEGF单抗注射液临床试验获伦理委员会审批报告】智通财经APP讯，赛升药业(300485.","url":"https://stock-news.laohu8.com/highlight/detail?id=2453567617","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453567617?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:53","pubTimestamp":1721638403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0028","III","BK1141","BK4134","BK0239","BK0012","300485","BK1576","BK1583","03347","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","stockEarnings":[{"period":"1week","weight":0.0103},{"period":"1month","weight":-0.0356},{"period":"3month","weight":0.1948},{"period":"6month","weight":0.0994},{"period":"1year","weight":-0.3253},{"period":"ytd","weight":-0.2564}],"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","perCapita":"9946股","boardName":"医药制造业","registeredCapital":"48166万元","compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0121},{"period":"3month","weight":0.1488},{"period":"6month","weight":0.0544},{"period":"1year","weight":0.0752},{"period":"ytd","weight":0.0957}],"survey":" 北京赛升药业股份有限公司的主营业务为注射针剂的研发、生产及销售,主导产品为生物生化药品，涉及心脑血管类疾病、免疫性疾病(抗肿瘤)和神经系统疾病三大用药领域。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。公司及赛而生物发明专利“单唾液酸四己糖神经节苷脂的制备方法以及单唾液酸四己糖神经节苷脂钠注射液或冻干粉针”(专利号ZL200910085592.0)荣获第二十届中国专利优秀奖。纤溶酶注射液被评为2023年年度生化生物企业优秀品牌。","serverTime":1732669351583,"listedPrice":38.46,"stockholders":"27529人(较上一季度减少1.65%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛升药业,300485,赛升药业股票,赛升药业股票老虎,赛升药业股票老虎国际,赛升药业行情,赛升药业股票行情,赛升药业股价,赛升药业股市,赛升药业股票价格,赛升药业股票交易,赛升药业股票购买,赛升药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}